Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 715

1.

Discovery of Novel Integrase Inhibitors Acting outside the Active Site Through High-Throughput Screening.

Aknin C, Smith EA, Marchand C, Andreola ML, Pommier Y, Metifiot M.

Molecules. 2019 Oct 12;24(20). pii: E3675. doi: 10.3390/molecules24203675.

2.

Tyrosyl-DNA Phosphodiesterase 1 and Topoisomerase I Activities as Predictive Indicators for Glioblastoma Susceptibility to Genotoxic Agents.

Wang W, Rodriguez-Silva M, Acanda de la Rocha AM, Wolf AL, Lai Y, Liu Y, Reinhold WC, Pommier Y, Chambers JW, Tse-Dinh YC.

Cancers (Basel). 2019 Sep 23;11(10). pii: E1416. doi: 10.3390/cancers11101416.

3.

Dual Processing of R-Loops and Topoisomerase I Induces Transcription-Dependent DNA Double-Strand Breaks.

Cristini A, Ricci G, Britton S, Salimbeni S, Huang SN, Marinello J, Calsou P, Pommier Y, Favre G, Capranico G, Gromak N, Sordet O.

Cell Rep. 2019 Sep 17;28(12):3167-3181.e6. doi: 10.1016/j.celrep.2019.08.041.

4.

The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib.

Marzi L, Szabova L, Gordon M, Weaver Ohler Z, Sharan SK, Beshiri ML, Etemadi M, Murai J, Kelly K, Pommier Y.

Clin Cancer Res. 2019 Oct 15;25(20):6206-6216. doi: 10.1158/1078-0432.CCR-19-0419. Epub 2019 Aug 13.

PMID:
31409613
5.

Beyond the unwinding: role of TOP1MT in mitochondrial translation.

Baechler SA, Dalla Rosa I, Spinazzola A, Pommier Y.

Cell Cycle. 2019 Oct;18(19):2377-2384. doi: 10.1080/15384101.2019.1646563. Epub 2019 Aug 9.

PMID:
31345095
6.

Targeting Topoisomerase I in the Era of Precision Medicine.

Thomas A, Pommier Y.

Clin Cancer Res. 2019 Jun 21. doi: 10.1158/1078-0432.CCR-19-1089. [Epub ahead of print] Review.

PMID:
31227499
7.

Mammalian Tyrosyl-DNA Phosphodiesterases in the Context of Mitochondrial DNA Repair.

Huang SN, Pommier Y.

Int J Mol Sci. 2019 Jun 20;20(12). pii: E3015. doi: 10.3390/ijms20123015. Review.

8.

Topoisomerase II-Induced Chromosome Breakage and Translocation Is Determined by Chromosome Architecture and Transcriptional Activity.

Canela A, Maman Y, Huang SN, Wutz G, Tang W, Zagnoli-Vieira G, Callen E, Wong N, Day A, Peters JM, Caldecott KW, Pommier Y, Nussenzweig A.

Mol Cell. 2019 Jul 25;75(2):252-266.e8. doi: 10.1016/j.molcel.2019.04.030. Epub 2019 Jun 12.

PMID:
31202577
9.

Identification of a ligand binding hot spot and structural motifs replicating aspects of tyrosyl-DNA phosphodiesterase I (TDP1) phosphoryl recognition by crystallographic fragment cocktail screening.

Lountos GT, Zhao XZ, Kiselev E, Tropea JE, Needle D, Pommier Y, Burke TR, Waugh DS.

Nucleic Acids Res. 2019 Jun 14. pii: gkz515. doi: 10.1093/nar/gkz515. [Epub ahead of print]

PMID:
31199869
10.

Synthesis and biological evaluation of 5-aminoethyl benzophenanthridone derivatives as DNA topoisomerase IB inhibitors.

Tang WL, Zhang Y, Hu DX, Yang H, Yu Q, Chen JW, Agama K, Pommier Y, An LK.

Eur J Med Chem. 2019 Sep 15;178:81-92. doi: 10.1016/j.ejmech.2019.05.074. Epub 2019 May 30.

PMID:
31176097
11.

Schlafen 11 (SLFN11), a restriction factor for replicative stress induced by DNA-targeting anti-cancer therapies.

Murai J, Thomas A, Miettinen M, Pommier Y.

Pharmacol Ther. 2019 Sep;201:94-102. doi: 10.1016/j.pharmthera.2019.05.009. Epub 2019 May 23. Review.

PMID:
31128155
12.

RNA Sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB.

Reinhold WC, Varma S, Sunshine M, Elloumi F, Ofori-Atta K, Lee S, Trepel JB, Meltzer PS, Doroshow JH, Pommier Y.

Cancer Res. 2019 Jul 1;79(13):3514-3524. doi: 10.1158/0008-5472.CAN-18-2047. Epub 2019 May 21.

PMID:
31113817
13.

Phosphatase 1 Nuclear Targeting Subunit, a Novel DNA Repair Partner of PARP1.

Murai J, Pommier Y.

Cancer Res. 2019 May 15;79(10):2460-2461. doi: 10.1158/0008-5472.CAN-19-0798.

PMID:
31092408
14.

Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II Study.

Thomas A, Vilimas R, Trindade C, Erwin-Cohen R, Roper N, Xi L, Krishnasamy V, Levy E, Mammen A, Nichols S, Chen Y, Velcheti V, Yin F, Szabo E, Pommier Y, Steinberg SM, Trepel JB, Raffeld M, Young HA, Khan J, Hewitt S, Lee JM.

J Thorac Oncol. 2019 Aug;14(8):1447-1457. doi: 10.1016/j.jtho.2019.04.026. Epub 2019 May 4.

PMID:
31063862
15.

Novel Deazaflavin Analogues Potently Inhibited Tyrosyl DNA Phosphodiesterase 2 (TDP2) and Strongly Sensitized Cancer Cells toward Treatment with Topoisomerase II (TOP2) Poison Etoposide.

Kankanala J, Ribeiro CJA, Kiselev E, Ravji A, Williams J, Xie J, Aihara H, Pommier Y, Wang Z.

J Med Chem. 2019 May 9;62(9):4669-4682. doi: 10.1021/acs.jmedchem.9b00274. Epub 2019 Apr 30.

PMID:
30998359
16.

The antitumor activity of CYB-L10, a human topoisomerase IB catalytic inhibitor.

Yu Q, Chen Y, Yang H, Zhang HL, Agama K, Pommier Y, An LK.

J Enzyme Inhib Med Chem. 2019 Dec;34(1):818-822. doi: 10.1080/14756366.2018.1516651.

17.

37PGenomics and pharmacogenomics analyses of cancer cell lines using the CellMinerCDB and CellMiner web-applications.

Reinhold W, Pommier Y.

Ann Oncol. 2019 Feb 1;30(Supplement_1). pii: mdz026.008. doi: 10.1093/annonc/mdz026.008. No abstract available.

PMID:
30810190
18.

Novel clinical indenoisoquinoline topoisomerase I inhibitors: a twist around the camptothecins.

Pommier Y, Cushman M, Doroshow JH.

Oncotarget. 2018 Dec 18;9(99):37286-37288. doi: 10.18632/oncotarget.26466. eCollection 2018 Dec 18. No abstract available.

19.

Novel screen for anti-cancer drugs that elevate chromosome instability (CIN) using human artificial chromosome (HAC).

Kouprina N, Pommier Y, Larionov V.

Oncotarget. 2018 Dec 7;9(96):36833-36835. doi: 10.18632/oncotarget.26406. eCollection 2018 Dec 7.

20.

The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesis.

Baechler SA, Factor VM, Dalla Rosa I, Ravji A, Becker D, Khiati S, Miller Jenkins LM, Lang M, Sourbier C, Michaels SA, Neckers LM, Zhang HL, Spinazzola A, Huang SN, Marquardt JU, Pommier Y.

Nat Commun. 2019 Jan 8;10(1):83. doi: 10.1038/s41467-018-07922-3.

21.

CellMinerCDB for Integrative Cross-Database Genomics and Pharmacogenomics Analyses of Cancer Cell Lines.

Rajapakse VN, Luna A, Yamade M, Loman L, Varma S, Sunshine M, Iorio F, Sousa FG, Elloumi F, Aladjem MI, Thomas A, Sander C, Kohn KW, Benes CH, Garnett M, Reinhold WC, Pommier Y.

iScience. 2018 Dec 21;10:247-264. doi: 10.1016/j.isci.2018.11.029. Epub 2018 Dec 12.

22.

Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[ c]pyrrolo[2,3- h][1,6]naphthyridin-5-one (BPN) Series.

Elsayed MSA, Nielsen JJ, Park S, Park J, Liu Q, Kim CH, Pommier Y, Agama K, Low PS, Cushman M.

J Med Chem. 2018 Dec 13;61(23):10440-10462. doi: 10.1021/acs.jmedchem.8b00510. Epub 2018 Nov 21.

PMID:
30460842
23.

Endogenous single-strand DNA breaks at RNA polymerase II promoters in Saccharomyces cerevisiae.

Hegedüs É, Kókai E, Nánási P, Imre L, Halász L, Jossé R, Antunovics Z, Webb MR, El Hage A, Pommier Y, Székvölgyi L, Dombrádi V, Szabó G.

Nucleic Acids Res. 2018 Nov 16;46(20):10649-10668. doi: 10.1093/nar/gky743.

24.

Discovery, Synthesis, and Evaluation of Oxynitidine Derivatives as Dual Inhibitors of DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1), and Potential Antitumor Agents.

Zhang XR, Wang HW, Tang WL, Zhang Y, Yang H, Hu DX, Ravji A, Marchand C, Kiselev E, Ofori-Atta K, Agama K, Pommier Y, An LK.

J Med Chem. 2018 Nov 21;61(22):9908-9930. doi: 10.1021/acs.jmedchem.8b00639. Epub 2018 Oct 31.

PMID:
30336023
25.

Systematic Analysis of Compounds Specifically Targeting Telomeres and Telomerase for Clinical Implications in Cancer Therapy.

Lee HS, Carmena M, Liskovykh M, Peat E, Kim JH, Oshimura M, Masumoto H, Teulade-Fichou MP, Pommier Y, Earnshaw WC, Larionov V, Kouprina N.

Cancer Res. 2018 Nov 1;78(21):6282-6296. doi: 10.1158/0008-5472.CAN-18-0894. Epub 2018 Aug 30.

26.

Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant Ube3a gene associated with Angelman syndrome.

Lee HM, Clark EP, Kuijer MB, Cushman M, Pommier Y, Philpot BD.

Mol Autism. 2018 Aug 17;9:45. doi: 10.1186/s13229-018-0228-2. eCollection 2018.

27.

TDP1 suppresses mis-joining of radiomimetic DNA double-strand breaks and cooperates with Artemis to promote optimal nonhomologous end joining.

Kawale AS, Akopiants K, Valerie K, Ruis B, Hendrickson EA, Huang SN, Pommier Y, Povirk LF.

Nucleic Acids Res. 2018 Sep 28;46(17):8926-8939. doi: 10.1093/nar/gky694.

28.

Acquired SETD2 mutation and impaired CREB1 activation confer cisplatin resistance in metastatic non-small cell lung cancer.

Kim IK, McCutcheon JN, Rao G, Liu SV, Pommier Y, Skrzypski M, Zhang YW, Giaccone G.

Oncogene. 2019 Jan;38(2):180-193. doi: 10.1038/s41388-018-0429-3. Epub 2018 Aug 9.

PMID:
30093630
29.

NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.

Burton JH, Mazcko C, LeBlanc A, Covey JM, Ji J, Kinders RJ, Parchment RE, Khanna C, Paoloni M, Lana S, Weishaar K, London C, Kisseberth W, Krick E, Vail D, Childress M, Bryan JN, Barber L, Ehrhart EJ, Kent M, Fan T, Kow K, Northup N, Wilson-Robles H, Tomaszewski J, Holleran JL, Muzzio M, Eiseman J, Beumer JH, Doroshow JH, Pommier Y.

Clin Cancer Res. 2018 Dec 1;24(23):5830-5840. doi: 10.1158/1078-0432.CCR-18-1498. Epub 2018 Jul 30.

PMID:
30061364
30.

HIV-1 Integrase-Targeted Short Peptides Derived from a Viral Protein R Sequence.

Zhao XZ, Métifiot M, Kiselev E, Kessl JJ, Maddali K, Marchand C, Kvaratskhelia M, Pommier Y, Burke TR Jr.

Molecules. 2018 Jul 26;23(8). pii: E1858. doi: 10.3390/molecules23081858.

31.

Novel Fluoroindenoisoquinoline Non-Camptothecin Topoisomerase I Inhibitors.

Marzi L, Agama K, Murai J, Difilippantonio S, James A, Peer CJ, Figg WD, Beck D, Elsayed MSA, Cushman M, Pommier Y.

Mol Cancer Ther. 2018 Aug;17(8):1694-1704. doi: 10.1158/1535-7163.MCT-18-0028. Epub 2018 May 10.

32.

Probing the evolutionary conserved residues Y204, F259, S400 and W590 that shape the catalytic groove of human TDP1 for 3'- and 5'-phosphodiester-DNA bond cleavage.

Kiselev E, Dexheimer TS, Marchand C, Huang SN, Pommier Y.

DNA Repair (Amst). 2018 Jun - Jul;66-67:64-71. doi: 10.1016/j.dnarep.2018.05.001. Epub 2018 May 2.

PMID:
29747024
33.

ONC201 kills breast cancer cells in vitro by targeting mitochondria.

Greer YE, Porat-Shliom N, Nagashima K, Stuelten C, Crooks D, Koparde VN, Gilbert SF, Islam C, Ubaldini A, Ji Y, Gattinoni L, Soheilian F, Wang X, Hafner M, Shetty J, Tran B, Jailwala P, Cam M, Lang M, Voeller D, Reinhold WC, Rajapakse V, Pommier Y, Weigert R, Linehan WM, Lipkowitz S.

Oncotarget. 2018 Apr 6;9(26):18454-18479. doi: 10.18632/oncotarget.24862. eCollection 2018 Apr 6.

34.

PRMT5-mediated arginine methylation of TDP1 for the repair of topoisomerase I covalent complexes.

Rehman I, Basu SM, Das SK, Bhattacharjee S, Ghosh A, Pommier Y, Das BB.

Nucleic Acids Res. 2018 Jun 20;46(11):5601-5617. doi: 10.1093/nar/gky291.

35.

Synthesis and structure-activity relationship of furoquinolinediones as inhibitors of Tyrosyl-DNA phosphodiesterase 2 (TDP2).

Yu LM, Hu Z, Chen Y, Ravji A, Lopez S, Plescia CB, Yu Q, Yang H, Abdelmalak M, Saha S, Agama K, Kiselev E, Marchand C, Pommier Y, An LK.

Eur J Med Chem. 2018 May 10;151:777-796. doi: 10.1016/j.ejmech.2018.04.024. Epub 2018 Apr 12.

36.

The evolving landscape of predictive biomarkers of response to PARP inhibitors.

Thomas A, Murai J, Pommier Y.

J Clin Invest. 2018 May 1;128(5):1727-1730. doi: 10.1172/JCI120388. Epub 2018 Apr 16.

37.

New fluorescence-based high-throughput screening assay for small molecule inhibitors of tyrosyl-DNA phosphodiesterase 2 (TDP2).

Ribeiro CJA, Kankanala J, Shi K, Kurahashi K, Kiselev E, Ravji A, Pommier Y, Aihara H, Wang Z.

Eur J Pharm Sci. 2018 Jun 15;118:67-79. doi: 10.1016/j.ejps.2018.03.021. Epub 2018 Mar 21.

38.

Mitochondrial tyrosyl-DNA phosphodiesterase 2 and its TDP2S short isoform.

Huang SN, Dalla Rosa I, Michaels SA, Tulumello DV, Agama K, Khiati S, Jean SR, Baechler SA, Factor VM, Varma S, Murai J, Miller Jenkins LM, Kelley SO, Pommier Y.

EMBO Rep. 2018 Mar;19(3). pii: e42139. doi: 10.15252/embr.201642139. Epub 2018 Feb 9.

39.

SLFN11 Blocks Stressed Replication Forks Independently of ATR.

Murai J, Tang SW, Leo E, Baechler SA, Redon CE, Zhang H, Al Abo M, Rajapakse VN, Nakamura E, Jenkins LMM, Aladjem MI, Pommier Y.

Mol Cell. 2018 Feb 1;69(3):371-384.e6. doi: 10.1016/j.molcel.2018.01.012.

40.

Overcoming Resistance to DNA-Targeted Agents by Epigenetic Activation of Schlafen 11 (SLFN11) Expression with Class I Histone Deacetylase Inhibitors.

Tang SW, Thomas A, Murai J, Trepel JB, Bates SE, Rajapakse VN, Pommier Y.

Clin Cancer Res. 2018 Apr 15;24(8):1944-1953. doi: 10.1158/1078-0432.CCR-17-0443. Epub 2018 Feb 1.

41.

Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.

Thomas A, Redon CE, Sciuto L, Padiernos E, Ji J, Lee MJ, Yuno A, Lee S, Zhang Y, Tran L, Yutzy W, Rajan A, Guha U, Chen H, Hassan R, Alewine CC, Szabo E, Bates SE, Kinders RJ, Steinberg SM, Doroshow JH, Aladjem MI, Trepel JB, Pommier Y.

J Clin Oncol. 2018 Jun 1;36(16):1594-1602. doi: 10.1200/JCO.2017.76.6915. Epub 2017 Dec 18.

42.

ALC1/CHD1L, a chromatin-remodeling enzyme, is required for efficient base excision repair.

Tsuda M, Cho K, Ooka M, Shimizu N, Watanabe R, Yasui A, Nakazawa Y, Ogi T, Harada H, Agama K, Nakamura J, Asada R, Fujiike H, Sakuma T, Yamamoto T, Murai J, Hiraoka M, Koike K, Pommier Y, Takeda S, Hirota K.

PLoS One. 2017 Nov 17;12(11):e0188320. doi: 10.1371/journal.pone.0188320. eCollection 2017.

43.

Synthesis, anti-cancer screening and tyrosyl-DNA phosphodiesterase 1 (Tdp1) inhibition activity of novel piperidinyl sulfamides.

Jun JH, Kumar V, Dexheimer TS, Wedlich I, Nicklaus MC, Pommier Y, Malhotra SV.

Eur J Pharm Sci. 2018 Jan 1;111:337-348. doi: 10.1016/j.ejps.2017.10.017. Epub 2017 Oct 13.

PMID:
29037996
44.

Transcription profiling suggests that mitochondrial topoisomerase IB acts as a topological barrier and regulator of mitochondrial DNA transcription.

Dalla Rosa I, Zhang H, Khiati S, Wu X, Pommier Y.

J Biol Chem. 2017 Dec 8;292(49):20162-20172. doi: 10.1074/jbc.M117.815241. Epub 2017 Oct 11.

45.

HTLV-1 bZIP factor suppresses TDP1 expression through inhibition of NRF-1 in adult T-cell leukemia.

Takiuchi Y, Kobayashi M, Tada K, Iwai F, Sakurada M, Hirabayashi S, Nagata K, Shirakawa K, Shindo K, Yasunaga JI, Murakawa Y, Rajapakse V, Pommier Y, Matsuoka M, Takaori-Kondo A.

Sci Rep. 2017 Oct 9;7(1):12849. doi: 10.1038/s41598-017-12924-0.

46.

Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer.

Ballestrero A, Bedognetti D, Ferraioli D, Franceschelli P, Labidi-Galy SI, Leo E, Murai J, Pommier Y, Tsantoulis P, Vellone VG, Zoppoli G.

J Transl Med. 2017 Oct 2;15(1):199. doi: 10.1186/s12967-017-1296-3.

47.

Effects of camptothecin or TOP1 overexpression on genetic stability in Saccharomyces cerevisiae.

Sloan R, Huang SN, Pommier Y, Jinks-Robertson S.

DNA Repair (Amst). 2017 Nov;59:69-75. doi: 10.1016/j.dnarep.2017.09.004. Epub 2017 Sep 18.

48.

Distribution bias and biochemical characterization of TOP1MT single nucleotide variants.

Zhang H, Seol Y, Agama K, Neuman KC, Pommier Y.

Sci Rep. 2017 Aug 17;7(1):8614. doi: 10.1038/s41598-017-09258-2.

49.

TDP1 is Critical for the Repair of DNA Breaks Induced by Sapacitabine, a Nucleoside also Targeting ATM- and BRCA-Deficient Tumors.

Al Abo M, Sasanuma H, Liu X, Rajapakse VN, Huang SY, Kiselev E, Takeda S, Plunkett W, Pommier Y.

Mol Cancer Ther. 2017 Nov;16(11):2543-2551. doi: 10.1158/1535-7163.MCT-17-0110. Epub 2017 Aug 11.

50.

Structure-Guided Optimization of HIV Integrase Strand Transfer Inhibitors.

Zhao XZ, Smith SJ, Maskell DP, Métifiot M, Pye VE, Fesen K, Marchand C, Pommier Y, Cherepanov P, Hughes SH, Burke TR Jr.

J Med Chem. 2017 Sep 14;60(17):7315-7332. doi: 10.1021/acs.jmedchem.7b00596. Epub 2017 Aug 10.

Supplemental Content

Loading ...
Support Center